scholarly journals Mimicking Myelodysplastic Syndrome: Importance of Differential Diagnosis

2021 ◽  
Vol 2021 ◽  
pp. 1-3
Author(s):  
Thomas Luo ◽  
Joanna Zurko ◽  
John Astle ◽  
Nirav N. Shah

Copper deficiency is a rare nutritional deficiency with hematological manifestations that mimic those found in myelodysplastic syndrome, a hematological malignancy incurable without allogeneic hematopoietic stem cell transplantation. Bone marrow biopsy findings and peripheral blood counts are oftentimes insufficient to differentiate the two conditions. Moreover, the symptoms of copper deficiency can arise years after the surgery, making diagnosis a challenge. In patients with new-onset pancytopenia, copper deficiency must be considered on the differential, especially in the setting of known risk factors such as bariatric surgery, zinc supplementation, and celiac disease. Herein, we present a case of a 61-year-old female with a remote history of gastric bypass being evaluated for MDS in the context of progressive pancytopenia and new-onset paresthesias. The patient was found to have low serum copper and ceruloplasmin. Copper supplementation largely resolved the hematological abnormalities, but the limb paresthesias remain. This case highlights the need to identify copper deficiency early and distinguish it from MDS in order to prevent permanent neurological deficits and catastrophic response should the patient undergo hematopoietic stem cell transplantation.

2011 ◽  
Vol 29 (5) ◽  
pp. 566-572 ◽  
Author(s):  
Sergio A. Giralt ◽  
Mary Horowitz ◽  
Daniel Weisdorf ◽  
Corey Cutler

Myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal hematopoietic stem-cell disorders that result in varying degrees of cytopenia and risk of transformation into acute leukemia. Allogeneic stem-cell transplantation (SCT) is the only known cure for this disease. The treatment is routinely used for younger patients, but only a minority of patients older than the age of 60 undergo this procedure. The overall MDS incidence is 3.3 per 100,000, but the incidence in patients older than age 70 is between 15 and 50 per 100,000. The median age at presentation is 76 years. Medicare-age patients 65 or older represent 80% of the total population receiving an MDS diagnosis. In the United States, one of the obstacles to SCT for older patients with MDS has been lack of third party reimbursement. On August 4, 2010, the Centers for Medicare and Medicaid Services released their Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Myelodysplastic Syndrome. This memo states: “Allogeneic HSCT for MDS is covered by Medicare only for beneficiaries with MDS participating in an approved clinical study that meets the criteria below…. ” In this review, we will summarize what is known regarding the role of allogeneic SCT in older patients as well as other elements that should be included within clinical trials that can provide the evidence necessary to demonstrate that allogeneic SCT should be a covered benefit for Medicare beneficiaries.


JBMTCT ◽  
2020 ◽  
Vol 2 (1) ◽  
pp. 16-19
Author(s):  
Mair Pedro De Souza ◽  
Fernanda Leite Souza Franceschi ◽  
Fernando Barroso Duarte ◽  
Diego Coutinho ◽  
Beatrice Araujo Duarte ◽  
...  

Mielodysplastic syndrome and hematopoietic stem cell transplantation based on genetic status.


Sign in / Sign up

Export Citation Format

Share Document